Last reviewed · How we verify
Calcipotriol plus hydrocortisone ointment
Calcipotriol (a vitamin D analogue) reduces skin cell proliferation and promotes differentiation, while hydrocortisone (a corticosteroid) suppresses inflammation and immune responses in the skin.
Calcipotriol (a vitamin D analogue) reduces skin cell proliferation and promotes differentiation, while hydrocortisone (a corticosteroid) suppresses inflammation and immune responses in the skin. Used for Psoriasis (plaque psoriasis), Atopic dermatitis.
At a glance
| Generic name | Calcipotriol plus hydrocortisone ointment |
|---|---|
| Sponsor | LEO Pharma |
| Drug class | Vitamin D analogue plus corticosteroid combination |
| Target | Vitamin D receptor (VDR) and glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriol acts as a selective vitamin D3 receptor agonist, normalizing keratinocyte differentiation and reducing hyperproliferation characteristic of psoriasis. Hydrocortisone provides rapid anti-inflammatory and immunosuppressive effects through glucocorticoid receptor activation. The combination leverages complementary mechanisms: the vitamin D analogue provides disease-modifying activity while the corticosteroid delivers faster symptomatic relief.
Approved indications
- Psoriasis (plaque psoriasis)
- Atopic dermatitis
Common side effects
- Skin irritation or burning at application site
- Hypercalcemia (with excessive use)
- Local skin atrophy (from corticosteroid component)
- Folliculitis
Key clinical trials
- Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds (PHASE3)
- Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment Compared With Tacalcitol Ointment in Patients With Psoriasis on the Face and Skin Folds (PHASE3)
- A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas (PHASE3)
- Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds (PHASE2)
- Vasoconstriction Trial With LEO 90100 Aerosol Foam (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Calcipotriol plus hydrocortisone ointment CI brief — competitive landscape report
- Calcipotriol plus hydrocortisone ointment updates RSS · CI watch RSS
- LEO Pharma portfolio CI